Characteristics of clinical trials associated with appeal and return on investment to participants: a review and framework.

Despite decades of investment in clinical research infrastructure, patient participation in clinical trials remains strikingly low. In the United States, fewer than 1 in 10 adults report ever being invited to participate in a clinical trial, and among those, less than half ultimately enroll. In onco...

Descripción completa

Detalles Bibliográficos
Publicado en:Oncologist Vol. 30; no. 10; pp. 1 - 10
Autores principales: Turizo, Maria J Fernandez, Velez, Maria A, Glenn, Beth, Cummings, Amy L, Segarra-Vazquez, Barbara, Gorbatov, Sarah, Park, Seung J, Shen, Collin, Lind-Lebuffe, Jackson P, Unger, Joseph M, Garon, Edward B
Formato: review tables/charts Journal Article
Publicado: Oxford University Press / USA Oct2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=189289118&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 189289118
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10837159
        IJ7
      jtl: Oncologist
      issn: 10837159
      maglogo: N
    pubinfo:
      dt: Oct2025
      vid: 30
      iid: 10
      pid: 622
      pub: Oxford University Press / USA
    artinfo:
      ui:
        189289118
        189289118
        189289118
        10.1093/oncolo/oyaf313
        189289118
      ppf: 1
      ppct: 9
      formats:
      tig:
        atl: Characteristics of clinical trials associated with appeal and return on investment to participants: a review and framework.
      aug:
        au:
          Turizo, Maria J Fernandez
          Velez, Maria A
          Glenn, Beth
          Cummings, Amy L
          Segarra-Vazquez, Barbara
          Gorbatov, Sarah
          Park, Seung J
          Shen, Collin
          Lind-Lebuffe, Jackson P
          Unger, Joseph M
          Garon, Edward B
        affil: Department of Medicine, Beth Israel Deaconess Medical Center, Deaconess Building, Suite 306, One Deaconess Road, MA 02215, United States
      sug:
        subj:
          Oncology
          Clinical Trials Economics
          Research Subjects
          Profits
          Cost Benefit Analysis
          Conceptual Framework
          Research, Medical
          Oncologic Care
          Costs and Cost Analysis
          Decision Making
          Motivation
          Research Subject Recruitment
          Eligibility Determination
      ab: Despite decades of investment in clinical research infrastructure, patient participation in clinical trials remains strikingly low. In the United States, fewer than 1 in 10 adults report ever being invited to participate in a clinical trial, and among those, less than half ultimately enroll. In oncology, across all adult cancer patients, only about 8% enroll in a clinical trial, regardless of eligibility or trial availability. Active engagement of their patients in cancer clinical trials substantially enhances scientific knowledge, and patient participation is required to obtain approval for novel therapeutics. Analyses focusing on evaluating whether clinical trial participation improves survival for participants have yielded conflicting results. Yet, there is limited data or metrics to assess the specific attributes of oncology trials that hold greater appeal or return on investment to participants, limiting researchers' ability to determine if these factors vary across different populations. Our group demonstrated that patients with limited English proficiency were unlikely to participate in studies not sponsored by industry as compared to industry-sponsored studies. If trial participation for specific populations can differ by sponsor type, it could also differ by the trial's appeal or return on investment. While the underrepresentation of racial and ethnic minority groups in trials is attributed to multiple factors, it is possible that patients from these groups are less likely to be offered participation in studies with higher appeal or return on investment, due to systemic biases, disparities in recruitment practices, and/or lack of access. In this manuscript, we propose a systematic framework for evaluating attributes of interventional oncology clinical trials, with an emphasis on the study's purpose, experimental design, and investigational agent. This framework aims to pinpoint characteristics that may enhance trials' appeal or return on investment to participants and could lay a foundation for future research. This will allow investigators to assess the return on investment of appeal of studies offered across different patient populations.
      pubtype: Academic Journal
      doctype:
        review
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N